Stock RHHBF ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG OTC Markets

Equities

RHHBF

CH0012032113

Market Closed - OTC Markets
Other stock markets
 03:13:03 2024-07-15 pm EDT 		5-day change 1st Jan Change
320 USD +6.67% Intraday chart for Roche Holding AG +5.96% +2.89%
06:25am Roche Receives Canadian Approval for Early-stage Lung Cancer Treatment MT
Jul. 15 ROCHE HOLDINGS AG : Sell rating from Goldman Sachs ZD

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Sales forecast by analysts have been recently revised upwards.

Weaknesses

  • The company's enterprise value to sales, at 3.65 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
+2.89% 234B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.53% 848B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.95% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.66% 363B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.06% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.18% 299B
C+
NOVARTIS AG Stock Novartis AG
+16.53% 225B
B-
AMGEN INC. Stock Amgen Inc.
+15.67% 179B
C+
PFIZER, INC. Stock Pfizer, Inc.
+2.47% 167B
C+
SANOFI Stock Sanofi
+2.41% 125B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RHHBF Stock
  5. Ratings Roche Holding AG